Introduction: Patients with locally advanced rectal cancer (LARC) are undergoing neoadjuvant chemoradiotherapy (NCRT) prior to surgery. Although in some patients the NCRT is known to prevent local recurrence, it is also accompanied by side effects. Accordingly, there is an unmet need to identify predictive markers allowing to identify non-responders to avoid its adverse effects. We monitored circulating tumor DNA (ctDNA) as a potential liquid biopsy-based biomarker. We have investigated ctDNA changes plasma during the early days of NCRT and its relationship to the overall therapy outcome. Methods and Patients: The studied cohort included 36 LARC patients (stage II or III) undergoing NCRT with subsequent surgical treatment. We have detected somatic mutations in tissue biopsies taken during endoscopic examination prior to the therapy. CtDNA was extracted from patient plasma samples prior to therapy and at the end of the first week. In order to optimize the analytical costs of liquid-biopsy testing, we have utilized a two-level approach in which first a low-cost detection method of denaturing capillary electrophoresis was used followed by examination of initially negative samples by a high-sensitivity BEAMING assay. The ctDNA was related to clinical parameters including tumor regression grade (TRG) and TNM tumor staging. Results: We have detected a somatic mutation in 33 out of 36 patients (91.7%). Seven patients (7/33, 21.2%) had ctDNA present prior to therapy. The ctDNA positivity before treatment reduced post-operative disease-free survival and overall survival by an average of 1.47 and 1.41 years, respectively (p = 0.015, and p = 0.010). In all patients, ctDNA was strongly reduced or completely eliminated from plasma by the end of the first week of NCRT, with no correlation to any of the parameters analyzed. Conclusions: The baseline ctDNA presence represented a statistically significant negative prognostic biomarker for the overall patient survival. As ctDNA was reduced indiscriminately from circulation of all patients, dynamics during the first week of NCRT is not suited for predicting the outcome of LARC. However, the general effect of rapid ctDNA disappearance apparently occurring during the initial days of NCRT is noteworthy and should further be studied.

Center for Applied Genomics of Solid Tumors Genomac Research Institute Prague Czechia

Department of Biology and Medical Genetics 2nd Faculty of Medicine Charles University and Motol University Hospital Prague Czechia

Department of Surgery 2nd Faculty of Medicine Charles University and Motol University Hospital Prague Czechia

Elphogene Prague Czechia

Institute of Biophysics and Informatics 1st Faculty of Medicine Charles University Prague Czechia

Zobrazit více v PubMed

Glynne-Jones R, Wyrwicz L, Tiret E, Brown G, Rödel C, Cervantes A, et al. Rectal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. (2017) 28(Suppl. 4):iv22–40. 10.1093/annonc/mdx224 PubMed DOI

Pahlman L, Bohe M, Cedermark B, Dahlberg M, Lindmark G, Sjodahl R, et al. The Swedish rectal cancer registry. Br J Surg. (2007) 94:1285–92. 10.1002/bjs.5679 PubMed DOI

Fokas E, Liersch T, Fietkau R, Hohenberger W, Beissbarth T, Hess C, et al. Tumor regression grading after preoperative chemoradiotherapy for locally advanced rectal carcinoma revisited: updated results of the CAO/ARO/AIO-94 trial. J Clin Oncol. (2014) 32:1554–62. 10.1200/JCO.2013.54.3769 PubMed DOI

Song C, Chung J-H, Kang S-B, Kim D-W, Oh H-K, Lee HS, et al. . Impact of tumor regression grade as a major prognostic factor in locally advanced rectal cancer after neoadjuvant chemoradiotherapy: a proposal for a modified staging system. Cancers. (2018) 10:319. 10.3390/cancers10090319 PubMed DOI PMC

Dworak O, Keilholz L, Hoffmann A. Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Colorectal Dis. (1997) 12:19–23. 10.1007/s003840050072 PubMed DOI

Contin P, Kulu Y, Bruckner T, Sturm M, Welsch T, Müller-Stich BP, et al. Comparative analysis of late functional outcome following preoperative radiation therapy or chemoradiotherapy and surgery or surgery alone in rectal cancer. Int J Colorect Dis. (2014) 29:165–75. 10.1007/s00384-013-1780-z PubMed DOI

Birgisson H, Pahlman L, Gunnarsson U, Glimelius B. Adverse effects of preoperative radiation therapy for rectal cancer: long-term follow-up of the Swedish rectal cancer trial. J Clin Oncol. (2005) 23:8697–705. 10.1200/JCO.2005.02.9017 PubMed DOI

Dayde D, Tanaka I, Jain R, Tai MC, Taguchi A. Predictive and prognostic molecular biomarkers for response to neoadjuvant chemoradiation in rectal cancer. Int J Mol Sci. (2017) 18:573. 10.3390/ijms18030573 PubMed DOI PMC

Vaupel P, Thews O, Hoeckel M. Treatment resistance of solid tumors: role of hypoxia and anemia. Med Oncol. (2001) 18:243–59. 10.1385/MO:18:4:243 PubMed DOI

DeVries AF, Kremser C, Hein PA, Griebel J, Krezcy A, Ofner D, et al. . Tumor microcirculation and diffusion predict therapy outcome for primary rectal carcinoma. Int J Radiat Oncol Biol Phys. (2003) 56:958–65. 10.1016/S0360-3016(03)00208-6 PubMed DOI

Devries AF, Griebel J, Kremser C, Judmaier W, Gneiting T, Kreczy A, et al. . Tumor microcirculation evaluated by dynamic magnetic resonance imaging predicts therapy outcome for primary rectal carcinoma. Cancer Res. (2001) 61:2513–6. 10.1016/s0360-3016(02)03106-1 PubMed DOI

Kremser C, Trieb T, Rudisch A, Judmaier W, de Vries A. Dynamic T(1) mapping predicts outcome of chemoradiation therapy in primary rectal carcinoma: sequence implementation and data analysis. J Magn Reson Imaging. (2007) 26:662–71. 10.1002/jmri.21034 PubMed DOI

Lambrecht M, Vandecaveye V, De Keyzer F, Roels S, Penninckx F, Van Cutsem E, et al. . Value of diffusion-weighted magnetic resonance imaging for prediction and early assessment of response to neoadjuvant radiochemotherapy in rectal cancer: preliminary results. Int J Radiat Oncol Biol Phys. (2012) 82:863–70. 10.1016/j.ijrobp.2010.12.063 PubMed DOI

Barbaro B, Vitale R, Valentini V, Illuminati S, Vecchio FM, Rizzo G, et al. . Diffusion-weighted magnetic resonance imaging in monitoring rectal cancer response to neoadjuvant chemoradiotherapy. Int J Radiat Oncol Biol Phys. (2012) 83:594–9. 10.1016/j.ijrobp.2011.07.017 PubMed DOI

Elmi A, Hedgire SS, Covarrubias D, Abtahi SM, Hahn PF, Harisinghani M. Apparent diffusion coefficient as a non-invasive predictor of treatment response and recurrence in locally advanced rectal cancer. Clin Radiol. (2013) 68:e524–31. 10.1016/j.crad.2013.05.094 PubMed DOI

Tate JG, Bamford S, Jubb HC, Sondka Z, Beare DM, Bindal N, et al. . COSMIC: the catalogue of somatic mutations in cancer. Nucleic Acids Res. (2019) 47:D941–7. 10.1093/nar/gky1015 PubMed DOI PMC

Lievre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF, et al. . KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. (2006) 66:3992–5. 10.1158/0008-5472.CAN-06-0191 PubMed DOI

Luna-Perez P, Segura J, Alvarado I, Labastida S, Santiago-Payan H, Quintero A. Specific c-K-ras gene mutations as a tumor-response marker in locally advanced rectal cancer treated with preoperative chemoradiotherapy. Ann Surg Oncol. (2000) 7:727–31. 10.1007/s10434-000-0727-0 PubMed DOI

Carpinetti P, Donnard E, Bettoni F, Asprino P, Koyama F, Rozanski A, et al. . The use of personalized biomarkers and liquid biopsies to monitor treatment response and disease recurrence in locally advanced rectal cancer after neoadjuvant chemoradiation. Oncotarget. (2015) 6:38360–71. 10.18632/oncotarget.5256 PubMed DOI PMC

Grimminger PP, Danenberg P, Dellas K, Arnold D, Rodel C, Machiels JP, et al. . Biomarkers for cetuximab-based neoadjuvant radiochemotherapy in locally advanced rectal cancer. Clin Cancer Res. (2011) 17:3469–77. 10.1158/1078-0432.CCR-10-2273 PubMed DOI

Garcia-Aguilar J, Chen Z, Smith DD, Li W, Madoff RD, Cataldo P, et al. . Identification of a biomarker profile associated with resistance to neoadjuvant chemoradiation therapy in rectal cancer. Ann Surg. (2011) 254:486–92. 10.1097/SLA.0b013e31822b8cfa PubMed DOI PMC

Spitz FR, Giacco GG, Hess K, Larry L, Rich TA, Janjan N, et al. . p53 immunohistochemical staining predicts residual disease after chemoradiation in patients with high-risk rectal cancer. Clin Cancer Res. (1997) 3:1685–90. PubMed

Rebischung C, Gerard JP, Gayet J, Thomas G, Hamelin R, Laurent-Puig P. Prognostic value of P53 mutations in rectal carcinoma. Int J Cancer. (2002) 100:131–5. 10.1002/ijc.10480 PubMed DOI

Chen MB, Wu XY, Yu R, Li C, Wang LQ, Shen W, et al. . P53 status as a predictive biomarker for patients receiving neoadjuvant radiation-based treatment: a meta-analysis in rectal cancer. PLoS ONE. (2012) 7:e45388. 10.1371/journal.pone.0045388 PubMed DOI PMC

Huh JW, Lee JH, Kim HR. Pretreatment expression of 13 molecular markers as a predictor of tumor responses after neoadjuvant chemoradiation in rectal cancer. Ann Surg. (2014) 259:508–15. 10.1097/SLA.0b013e31829b3916 PubMed DOI

Kudrimoti M, Lee EY, Kang Y, Ahmed M, Mohiuddin M. Genetic markers predictive of response to induction chemoradiotherapy for locally advanced rectal cancers. J Ky Med Assoc. (2007) 105:18–22. PubMed

Osumi H, Shinozaki E, Yamaguchi K, Zembutsu H. Clinical utility of circulating tumor DNA for colorectal cancer. Cancer Sci. (2019) 110:1148–55. 10.1111/cas.13972 PubMed DOI PMC

Meddeb R, Dache ZAA, Thezenas S, Otandault A, Tanos R, Pastor B, et al. . Quantifying circulating cell-free DNA in humans. Sci Rep. (2019) 9:5220. 10.1038/s41598-019-41593-4 PubMed DOI PMC

Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, Li M, et al. . Circulating mutant DNA to assess tumor dynamics. Nat Med. (2008) 14:985–90. 10.1038/nm.1789 PubMed DOI PMC

Ondrouskova E, Hrstka R. [Circulating tumor DNA in blood and its utilization as a potential biomarker for cancer]. Klin Onkol. (2015) 28(Suppl. 2):2s69–74. 10.14735/amko20152S69 PubMed DOI

Sefrioui D, Sarafan-Vasseur N, Beaussire L, Baretti M, Gangloff A, Blanchard F, et al. . Clinical value of chip-based digital-PCR platform for the detection of circulating DNA in metastatic colorectal cancer. Dig Liver Dis. (2015) 47:884–90. 10.1016/j.dld.2015.05.023 PubMed DOI

Spindler KL, Pallisgaard N, Andersen RF, Jakobsen A. Changes in mutational status during third-line treatment for metastatic colorectal cancer–results of consecutive measurement of cell free DNA, KRAS and BRAF in the plasma. Int J Cancer. (2014) 135:2215–22. 10.1002/ijc.28863 PubMed DOI

Tie J, Kinde I, Wang Y, Wong HL, Roebert J, Christie M, et al. . Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer. Ann Oncol. (2015) 26:1715–22. 10.1093/annonc/mdv177 PubMed DOI PMC

Khier S, Lohan L. Kinetics of circulating cell-free DNA for biomedical applications: critical appraisal of the literature. Future Sci OA. (2018) 4:Fso295. 10.4155/fsoa-2017-0140 PubMed DOI PMC

Minarik M, Minarikova L, Hrabikova M, Minarikova P, Hrabal P, Zavoral M. Application of cycling gradient capillary electrophoresis to detection of APC, K-ras, and DCC point mutations in patients with sporadic colorectal tumors. Electrophoresis. (2004) 25:1016–21. 10.1002/elps.200305770 PubMed DOI

Prochazkova K, Pavlikova K, Minarik M, Sumerauer D, Kodet R, Sedlacek Z. Somatic TP53 mutation mosaicism in a patient with Li-Fraumeni syndrome. Am J Med Genet A. (2009) 149a:206–11. 10.1002/ajmg.a.32574 PubMed DOI

Hinselwood DC, Abrahamsen TW, Ekstrom PO. BRAF mutation detection and identification by cycling temperature capillary electrophoresis. Electrophoresis. (2005) 26:2553–61. 10.1002/elps.200410427 PubMed DOI

Fiala O, Pesek M, Finek J, Benesova L, Bortlicek Z, Minarik M. Gene mutations in squamous cell NSCLC: insignificance of EGFR, KRAS and PIK3CA mutations in prediction of EGFR-TKI treatment efficacy. Anticancer Res. (2013) 33:1705–11. 10.1016/S0169-5002(13)70293-9 PubMed DOI

Levy M, Benesova L, Lipska L, Belsanova B, Minarikova P, Veprekova G, et al. . Utility of cell-free tumour DNA for post-surgical follow-up of colorectal cancer patients. Anticancer Res. (2012) 32:1621–6. PubMed

Diehl F, Li M, He Y, Kinzler KW, Vogelstein B, Dressman D. BEAMing: single-molecule PCR on microparticles in water-in-oil emulsions. Nat Methods. (2006) 3:551–9. 10.1038/nmeth898 PubMed DOI

Team. RDC A Language and Environment For Statistical Computing. Vienna: R Foundation for Statistical Computing; (2008).

Zitt M, Muller HM, Rochel M, Schwendinger V, Goebel G, Devries A, et al. . Circulating cell-free DNA in plasma of locally advanced rectal cancer patients undergoing preoperative chemoradiation: a potential diagnostic tool for therapy monitoring. Dis Markers. (2008) 25:159–65. 10.1155/2008/598071 PubMed DOI PMC

Agostini M, Pucciarelli S, Enzo MV, Del Bianco P, Briarava M, Bedin C, et al. . Circulating cell-free DNA: a promising marker of pathologic tumor response in rectal cancer patients receiving preoperative chemoradiotherapy. Ann Surg Oncol. (2011) 18:2461–8. 10.1245/s10434-011-1638-y PubMed DOI

Sun W, Li G, Wan J, Zhu J, Shen W, Zhang Z. Circulating tumor cells: a promising marker of predicting tumor response in rectal cancer patients receiving neoadjuvant chemo-radiation therapy. Oncotarget. (2016) 7:69507–17. 10.18632/oncotarget.10875 PubMed DOI PMC

Li M, Xiao W, Zhao GQ, Guo Z, Yang X, Lin S, et al. Predictive value of circulating tumor DNA in locally advanced rectal cancer patients receiving neoadjuvant radiochemotherapy. J Clin Oncol. (2017) 35(Suppl. 15):e15125 10.1200/JCO.2017.35.15_suppl.e15125 DOI

Yang L, Wang Y, Shen L, Wan J, Deng W, Zhu J, et al. Predicting treatment outcome of rectal cancer patients underwent neoadjuvant chemoradiotherapy by ctDNA: The potential use of ctDNA monitoring as organ-sparing approach. J Clin Oncol. (2018) 36(Suppl. 15):3608 10.1200/JCO.2018.36.15_suppl.3608 DOI

Benesova L, Belsanova B, Suchanek S, Kopeckova M, Minarikova P, Lipska L, et al. . Mutation-based detection and monitoring of cell-free tumor DNA in peripheral blood of cancer patients. Anal Biochem. (2013) 433:227–34. 10.1016/j.ab.2012.06.018 PubMed DOI

Tie J, Cohen JD, Wang Y, Li L, Christie M, Simons K, et al. . Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer: a prospective biomarker study. Gut. (2018) 68:663–71. 10.1136/gutjnl-2017-315852 PubMed DOI PMC

Hrebien S, Citi V, Garcia-Murillas I, Cutts R, Fenwick K, Kozarewa I, et al. . Early ctDNA dynamics as a surrogate for progression-free survival in advanced breast cancer in the BEECH trial. Ann Oncol. (2019) 30:945–52. 10.1093/annonc/mdz085 PubMed DOI PMC

Osumi H, Shinozaki E, Yamaguchi K, Zembutsu H. Early change in circulating tumor DNA as a potential predictor of response to chemotherapy in patients with metastatic colorectal cancer. Sci Rep. (2019) 9:17358. 10.1038/s41598-019-53711-3 PubMed DOI PMC

Reece M, Saluja H, Hollington P, Karapetis CS, Vatandoust S, Young GP, et al. . The use of circulating tumor DNA to monitor and predict response to treatment in colorectal cancer. Front Genet. (2019) 10:1118. 10.3389/fgene.2019.01118 PubMed DOI PMC

Kustanovich A, Schwartz R, Peretz T, Grinshpun A. Life and death of circulating cell-free DNA. Cancer Biol Ther. (2019) 20:1057–67. 10.1080/15384047.2019.1598759 PubMed DOI PMC

Vanpouille-Box C, Alard A, Aryankalayil MJ, Sarfraz Y, Diamond JM, Schneider RJ, et al. . DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity. Nat Commun. (2017) 8:15618. 10.1038/ncomms15618 PubMed DOI PMC

Lyskjaer I, Kronborg CS, Rasmussen MH, Sorensen BS, Demuth C, Rosenkilde M, et al. . Correlation between early dynamics in circulating tumour DNA and outcome from FOLFIRI treatment in metastatic colorectal cancer. Sci Rep. (2019) 9:11542. 10.1038/s41598-019-47708-1 PubMed DOI PMC

Vymetalkova V, Cervena K, Bartu L, Vodicka P. Circulating cell-free DNA and colorectal cancer: a systematic review. Int J Mol Sci. (2018) 19:3356. 10.3390/ijms19113356 PubMed DOI PMC

Raja R, Kuziora M, Brohawn PZ, Higgs BW, Gupta A, Dennis PA, et al. . Early reduction in ctDNA predicts survival in patients with lung and bladder cancer treated with durvalumab. Clin Cancer Res. (2018) 24:6212–6222. 10.1158/1078-0432.CCR-18-0386 PubMed DOI

Husain H, Melnikova VO, Kosco K, Woodward B, More S, Pingle SC, et al. . Monitoring daily dynamics of early tumor response to targeted therapy by detecting circulating tumor DNA in urine. Clin Cancer Res. (2017) 23:4716–4723. 10.1158/1078-0432.CCR-17-0454 PubMed DOI PMC

Khakoo S, Carter PD, Brown G, Valeri N, Picchia S, Bali MA, et al. . MRI tumor regression grade and circulating tumor DNA as complementary tools to assess response and guide therapy adaptation in rectal cancer. Clin Cancer Res. (2020) 26:183–92. 10.1158/1078-0432.CCR-19-1996 PubMed DOI

Detection and Quantification of ctDNA for Longitudinal Monitoring of Treatment in Non-Small Cell Lung Cancer Patients Using a Universal Mutant Detection Assay by Denaturing Capillary Electrophoresis